Alnylam will invest $250 million in its US manufacturing facility in order to increase its ability to meet the growing global demand for RNAi therapeutics.¹ Specifically, this investment will add an enzymatic ligation platform to the facility.

The expansion is slated for the company’s facility in Norton, Massachusetts, which opened in 2021.

How will the investment impact Anlylam's manufacturing capabilities?

In a press release announcing the investment, Alnylam chief executive officer Yvonne Greenstreet, MD, MBA, said, “At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility. This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.”

Over the past year, there has been an increase in domestic pharma manufacturing investments. This is likely the result of efforts of the Trump administration to increase domestic manufacturing and reduce the reliance on foreign imports.

Alnylam did not specifically cite the Trump administration or tariffs in its announcement.

“Alnylam represents the world-class health care innovation Massachusetts is known for. Alnylam has been a leader in life sciences in our state for over two decades,” said Governor Maura Healey. “Their scientific breakthroughs in siRNA manufacturing have transformed care by providing RNAi therapeutics to people who need it most, while creating thousands of jobs across our state. We're excited to support their growth through the expansion of a manufacturing facility in Southeastern Mass., and we're grateful for their continued investment in Massachusetts.”

Dr. Kirk Taylor, president and CEO of the Massachusetts Life Sciences Center (MLSC), added, “Alnylam’s continued investment in Massachusetts underscores the Commonwealth’s role as a global leader in biomanufacturing. This expansion will bring high-quality jobs to this area and ensure patients worldwide have the opportunity to benefit from medicines made right here in Massachusetts. We look forward to deepening our partnership as we work together to advance the thriving life sciences ecosystem here in the Commonwealth.”

In the same press release, Alnylam’s chief technical operations and quality officer Timothy Maines said, “Manufacturing oligonucleotide-based medicines is highly complex, and the current manufacturing technology will struggle to meet increased demand. We have successfully applied a reproducible, less time-intensive process that increases throughput while maintaining the highest quality standards. The expansion of our Norton facility presents an opportunity to reinvent what’s possible in oligonucleotide manufacturing.”

Alnylam recent announced changes to its board of directors.² Director. Mike Bonney and Carolyn Bertozzi, Ph.D., stepped down effective on December 2. Stuart Arbuckle will joing the board starting in January of 2026.

In a press release, Greenstreet said, “We are deeply grateful to Mike and Carolyn for their leadership, strategic insight, and unwavering commitment to Alnylam’s mission. Their contributions have helped shape Alnylam into the global R&D and commercial leader it is today. We thank them for their service and wish them the very best in their future endeavors.”

Amy Schulman, chair of the Alnylam board of directors, added, “We are delighted to welcome Stuart to our Board. He brings a valuable combination of commercial expertise and commitment to scientific innovation that will support our next phase of growth as we continue advancing RNAi therapeutics for patients worldwide. I join Yvonne in thanking Mike and Carolyn for their contributions.”

Sources

1. Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics. Alnylam. December 17, 2025. https://investors.alnylam.com/press-release?id=29466
2. Alnylam Pharmaceuticals Announces Changes to Board of Directors. Alnylam. December 3, 2025. Accessed December 19, 2025. https://investors.alnylam.com/press-release?id=29446